Skip to main content
Monday, November 16, 2026Nov 16

U.S. clears first ‘living drug’ for tough childhood leukemia

Stella Burnette, 2, squats down next to her tired brother Tripper Burnette, 6, Tues., June 6, 2017, during the ground breaking ceremony at the site for the new Erlanger Children's Hospital on Third Street in Chattanooga, Tenn. Stella recently went through treatment for acute myeloid leukemia and is an outpatient of Erlanger's Children's Hospital
Stella Burnette, 2, squats down next to her tired brother Tripper Burnette, 6, Tues., June 6, 2017, during the ground breaking ceremony at the site for the new Erlanger Children's Hospital on Third Street in Chattanooga, Tenn. Stella recently went through treatment for acute myeloid leukemia and is an outpatient of Erlanger's Children's Hospital

WASHINGTON (AP) – Opening a new era in cancer care, U.S. health officials on Wednesday approved a breakthrough treatment that genetically engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia.

The Food and Drug Administration called the approval historic, the first gene therapy to hit the U.S. market. Made from scratch for every patient, it’s one of a wave of “living drugs” under development to fight additional blood cancers and other tumors, too.

Novartis Pharmaceuticals set the price for its one-time infusion of so-called “CAR-T cells” at $475,000, but said there would be no charge for patients who didn’t show a response within a month.

“This is a brand new way of treating cancer,” said Dr. Stephan Grupp of Children’s Hospital of Philadelphia, who treated the first child with CAR-T cell therapy – a girl who’d been near death but now is cancer-free for five years and counting. “That’s enormously exciting.”

CAR-T treatment uses gene therapy techniques not to fix disease-causing genes but to turbocharge T cells, immune system soldiers that cancer too often can evade. Researchers filter those cells from a patient’s blood, reprogram them to harbor a “chimeric antigen receptor” or CAR that zeroes in on cancer, and grow hundreds of millions of copies. Returned to the patient, the revved-up cells can continue multiplying to fight disease for months or years.